Výsledky vyhledávání - "Kai Vogtlaender"

Safety profile of gadoxetate disodium in elderly patients (≥65 years)

Autor: Susan Dohannish, Kai Vogtlaender, Jan Endrikat, Josy Breuer, Carsten Schwenke

Publikováno v: Acta Radiologica (Stockholm, Sweden : 1987)

Background Safety data on routine clinical use of gadoxetate disodium in elderly patients is not reported yet. Purpose To assess the safety of liver specific gadoxetate disodium in contrast enhanced magnetic resonance imaging in elderly patients (≥

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28348092b6a3b8f82e0ccbc3829f2d24
https://doi.org/10.1177/0284185117700673

Zobrazit plný text záznamu

Safety of Gadobutrol

Autor: Josy Breuer, Thomas Balzer, Jan Endrikat, Susan Dohanish, Kai Vogtlaender

Publikováno v: Investigative Radiology. 51:537-543

ObjectiveThe aim of this study was to provide a systematic safety analysis of gadobutrol after more than 29 million applications in clinical routine.Materials and MethodsForty-two clinical development phase II to IV studies on gadobutrol or comparato

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dac33f96fd6013588f6710ac53ec5dec
https://doi.org/10.1097/rli.0000000000000270

Zobrazit plný text záznamu

Riociguat in Combination With Prostacyclin Analogs for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of the PATENT Studies

Autor: Marius Hoeper, Ioana R. Preston, Pavel Jansa, Carmine Dario Vizza, David Langleben, Hossein Ardeschir Ghofrani, Sylvia Nikkho, Nicholas Hill, Kai Vogtlaender

Publikováno v: Chest. 148:922A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b82e1d75a6eda0f1d760b4234fcfa66
https://doi.org/10.1378/chest.2276665

Zobrazit plný text záznamu

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban

Autor: Alexander G.G. Turpie, Frank Misselwitz, Kai Vogtlaender, Dagmar Kubitza, Ajay K. Kakkar, Sylvia Haas, Bengt I. Eriksson, Scott D. Berkowitz, Michael R. Lassen, Michael Gent, Wolfgang Mueck

Publikováno v: Blood. 114:2099-2099

Abstract 2099 Poster Board II-76 Rivaroxaban is a new, oral, direct Factor Xa inhibitor with a linear dose-relationship between Factor Xa inhibition and drug concentrations in plasma. It also affects global clotting tests such as prothrombin time (PT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de57ec25c1f51e3ceff29e5ebd641a74
https://doi.org/10.1182/blood.v114.22.2099.2099

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání